Drugs / Moonshot antibodies
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06674538 | Dec 2024 → Jan 2027 expected | malignant soft tissue neoplasm | Moonshot Antibodies | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moonshot antibodies | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06674538 ↗ |
| Action | Deplete | “so that the body can kill the cancer cells” NCT06674538 ↗ |
| Route | Other | “through a series of infusions” NCT06674538 ↗ |